Russia agrees to produce coronavirus vaccine Sputnik V in India

  


MOSCOW (Reuters) - Russia's sovereign wealth fund and Indian pharmaceutical company Hetero have agreed to produce over 100 million doses per year in India of the Sputnik V vaccine against COVID-19, according to a statement on the Sputnik V Twitter account on Friday.

Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and marketing it globally, plan to start production of Sputnik V in India at the beginning of 2021, the statement said.

Phase II-III trials are ongoing in India, the statement said. Drugmaker Dr Reddy's Laboratories Ltd has said it expects late-stage trials to be completed by as early as March 2021.

Read Complete Article


Comments

Popular posts from this blog

Tech billionaires making friends with Big Brother

Poco X3 Pro review: Good performance, modest cameras but unwieldy and heavy

OnePlus Watch review: Solid for starters, but not without software snags